Skip to main content
Erschienen in:

15.01.2019 | original report

Investigation of seasonal frequency and pathogens in febrile neutropenia

verfasst von: Seray Karagöz Özdemir, Utku Iltar, Ozan Salim, Orhan Kemal Yücel, Ramazan Erdem, Özge Turhan, Levent Undar

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Summary

Background

In patients with hematological malignancies, febrile neutropenia (FEN) is the most frequent complication and the most important cause of mortality. Various risk factors have been identified for severe infection in neutropenic patients. However, to the best of our knowledge, it is not defined whether there is a change in the risk of febrile neutropenia according to seasons. The first aim of study was to determine the difference in frequency of febrile neutropenic episodes (FNEs) according to months and seasons. The second aim was to document isolated pathogens, as well as demographical and clinical characteristics of patients.

Methods

In the study, 194 FNEs of 105 patients who have been followed with hematological malignancies between June 2013 and May 2014 were evaluated retrospectively.

Results

Although the number of FNEs increased in autumn, there was no significant difference in frequency of FNEs between months (p = 0.564) and seasons (p = 0.345). There was no isolated pathogen in 54.6% of FNEs. In 45.4% of 194 FNEs, pathogens were isolated. Of all pathogens, 50.4% were gram negative bacteria, 29.2% were gram positive bacteria, 13.3% were viruses, 5.3% were fungi, and 1.8% were parasites.

Conclusıons

The frequency of FEN does not change according to months or seasons. Also, the relative proportions of different pathogens in the cause of FEN do not vary according to seasons.
Literatur
1.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.CrossRef Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.CrossRef
2.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of Americaa. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427–31.CrossRef Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of Americaa. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427–31.CrossRef
3.
Zurück zum Zitat Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328(18):1323–32. Review.CrossRef Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993;328(18):1323–32. Review.CrossRef
4.
Zurück zum Zitat Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972;77(5):707–14.CrossRef Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972;77(5):707–14.CrossRef
5.
Zurück zum Zitat Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145(9):1621–9.CrossRef Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med. 1985;145(9):1621–9.CrossRef
6.
Zurück zum Zitat Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730–51.CrossRef Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730–51.CrossRef
7.
Zurück zum Zitat Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36(9):1103–10. Epub 2003 Apr 14.CrossRef Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36(9):1103–10. Epub 2003 Apr 14.CrossRef
8.
Zurück zum Zitat Holland T, Fowler VG Jr, Shelburne SA 3rd. Invasive gram-positive bacterial infection in cancer patients. Clin Infect Dis. 2014;59(Suppl 5):S331–S4.CrossRef Holland T, Fowler VG Jr, Shelburne SA 3rd. Invasive gram-positive bacterial infection in cancer patients. Clin Infect Dis. 2014;59(Suppl 5):S331–S4.CrossRef
9.
Zurück zum Zitat Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis. 2002;15(4):377–82. Review.CrossRef Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis. 2002;15(4):377–82. Review.CrossRef
10.
Zurück zum Zitat Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005;103(6):1103–13. Review.CrossRef Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005;103(6):1103–13. Review.CrossRef
11.
Zurück zum Zitat Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–9.CrossRef Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–9.CrossRef
12.
Zurück zum Zitat Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;20;31(6):794–810.CrossRef Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;20;31(6):794–810.CrossRef
13.
Zurück zum Zitat Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996;23(4):795–805.CrossRef Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996;23(4):795–805.CrossRef
14.
Zurück zum Zitat Kirkpatrick GL. The common cold. Prim Care. 1996;23(4):657–75. Review.CrossRef Kirkpatrick GL. The common cold. Prim Care. 1996;23(4):657–75. Review.CrossRef
15.
Zurück zum Zitat Heikkinen T, Järvinen A. The common cold. Lancet. 2003;361(9351):51–9.CrossRef Heikkinen T, Järvinen A. The common cold. Lancet. 2003;361(9351):51–9.CrossRef
Metadaten
Titel
Investigation of seasonal frequency and pathogens in febrile neutropenia
verfasst von
Seray Karagöz Özdemir
Utku Iltar
Ozan Salim
Orhan Kemal Yücel
Ramazan Erdem
Özge Turhan
Levent Undar
Publikationsdatum
15.01.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0468-z

Weitere Artikel der Ausgabe 2/2019

memo - Magazine of European Medical Oncology 2/2019 Zur Ausgabe